Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.

"Conflict of interest: This study was sponsored by Vertex Pharmaceuticals Incorporated. The sponsors were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript.: S.L. Flamm has served as a remunerated consultant/lecturer for Bristol-Myers Squibb, AbbVie, Gilead Sciences, Merck & Co., and Vertex Pharmaceuticals Incorporated, and has received grants/research support from AbbVie, Achillion, Anadys Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., Pfizer, and Vertex Pharmaceuticals Incorporated. He has also served as an advisor or review committee member for Gilead Sciences, Merck & Co., and Vertex Pharmaceuticals Incorporated. PJ Pockros has served as a remunerated consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., Novartis, and Vertex Pharmaceuticals Incorporated, and has received research grants from Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., and Vertex Pharmaceuticals Incorporated. He has also received fees for non-CME services from Genentech, Merck & Co., and Vertex Pharmaceuticals Incorporated. L. Bengtsson is an employee of Vertex Pharmaceuticals Incorporated and may own stock or stock options in that company. M. Friedman was an employee of Vertex Pharmaceuticals Incorporated at the time of this research and may own or may have owned stock or stock options in that company."

"Conflict of interest: This study was sponsored by Vertex Pharmaceuticals Incorporated. The sponsors were involved in study design, data collection and analysis, decision to publish, and preparation of the manuscript."